Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Jasper Therapeutics, Inc. - Class A (JSPR)
Company Research
Source: GlobeNewswire
REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the 23rd Annual Needham Virtual Healthcare Conference at 11am EDT on April 8, 2024. A live webcast of the presentation will be available on the Events & News – Presentations page of Jasper's Investor Relations website. An archived replay of the presentation will be available on Jasper's website for 30 days following the live broadcast. Inducement GrantOn April 1, 2024, four new employees were awarded grants of options to purchase an aggregate of 22,400 shares of voting common stock (the “Options”). Each Option was granted pursuant to the Jasper Therapeutics, Inc. Amended and Restated 2022 Induc
Show less
Read more
Impact Snapshot
Event Time:
JSPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JSPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JSPR alerts
High impacting Jasper Therapeutics, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
JSPR
News
- Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $65.00 price target on the stock.MarketBeat
- Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $70.00 price target on the stock.MarketBeat
- Jasper Therapeutics (JSPR) Is a Great Choice for 'Trend' Investors, Here's Why [Yahoo! Finance]Yahoo! Finance
- Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference [Yahoo! Finance]Yahoo! Finance
- Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceGlobeNewswire
JSPR
Sec Filings
- 4/22/24 - Form ARS
- 4/22/24 - Form DEFA14A
- 4/22/24 - Form DEF
- JSPR's page on the SEC website